SCHEMBL769510

SCHEMBL769510

CC1CCCN(C(=O)CCCC(=O)N2CCCC3CCCC=C32)C1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.55
MEN1 O00255 3/20 0.55
POLB P06746 2/20 0.55
MAPT P10636 1/20 0.55
HPGD P15428 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
ALDH1A1 P00352 4/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.45
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
HSD17B10 Q99714 1/20 0.42
NPC1 O15118 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RAB9A P51151 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770586 0.98 KMT2A (0.55) KMT2AMEN1POLBMAPTHPGD
SCHEMBL769760 0.95 HPGD (0.54) KMT2AMEN1POLBMAPTHPGD
SCHEMBL770262 0.91 KMT2A (0.43) KMT2AMEN1POLBMAPTHPGD
SCHEMBL771156 0.88 KMT2A (0.43) KMT2AMEN1POLBMAPTHPGD
SCHEMBL770471 0.88 NPC1 (0.56) KMT2AMEN1POLBMAPTHPGD
SCHEMBL771268 0.88 HPGD (0.48) KMT2AMEN1POLBMAPTHPGD
SCHEMBL770903 0.87 CHRM2 (0.42) KMT2AMEN1POLBMAPTHPGD
SCHEMBL770210 0.87 ATM (0.47) KMT2AMEN1MAPTHPGDSMN1; SMN2
SCHEMBL770616 0.86 MAPT (0.36) KMT2AMEN1POLBMAPTHPGD
SCHEMBL769764 0.86 HPGD (0.43) KMT2AMEN1POLBMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 KMT2A 3868/4885MEN1 827/4885POLB 375/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 KMT2A 3893/4885MEN1 823/4885POLB 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.